IPN (IPN) News
Follow IPN (IPN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Ipsen Q3 Sales Rise 28%, Company Upgrades FY26 Outlook
Ipsen said third-quarter total sales rose 28%, helped by its rare disease division, and upgraded its annual outlook.
EARNINGS | Oct 22, 2026, 07:09 AM UTC
M
Ipsen Q3 Sales Rise 28% on Core Portfolio
EARNINGS | Oct 22, 2026, 05:27 AM UTC
M
Ipsen Reports Q3 Total Sales of €1,173.9 Million
EARNINGS | Oct 22, 2026, 05:09 AM UTC
M
Ipsen Upgrades Full-Year Guidance After Nine-Month Sales Growth
Ipsen reported sales for the first nine months and third quarter of 2026 and further upgraded its full-year guidance.
EARNINGS | Oct 22, 2026, 05:00 AM UTC
L
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
Aggregated presentation by day and by marketAttachment
NEWS | Sep 28, 2026, 04:08 PM UTC
M
Ipsen shares drop after FDA approval of U.S. generic rival
Ipsen shares fell 6.6% to a seven-month low of 145.60 euros in morning European trade after the FDA approved a U.S. generic competitor to Ipsen’s flagship hormone drug earlier than expected.
EQUITY | Sep 21, 2026, 10:02 AM UTC
L
Ipsen buy-back programme under MAR Article 5, week 36 of 2025
Ipsen’s buy-back programme reports activity for week 36 of 2025 under MAR Article 5, with aggregated daily and market attachment presentation.
EQUITY | Sep 07, 2026, 04:08 PM UTC
L
Ipsen buy-back programme update: MAR Art 5 week 35, 2026
Ipsen buy-back programme update under MAR Article 5 for week 35 of 2026.
EQUITY | Aug 31, 2026, 04:08 PM UTC